Plumbagin (Synonyms: 白花丹素; 2-Methyljuglone)

目录号: HY-N1497 纯度: 99.39%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Plumbagin (2-Methyljuglone) 是从 Plumbago zeylanica 中得到的萘醌类物质，具有抗肿瘤、抗增殖活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Plumbagin Chemical Structure

CAS No. : 481-42-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥1045	In-stock
50 mg	￥950	In-stock
100 mg	￥1500	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Plumbagin:

Plumbagin (Standard) 询价

MCE 顾客使用本产品发表的 2 篇科研文献

Plumbagin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica, exhibits anticancer and antiproliferative activities^[1].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.4 μM Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
A549	IC₅₀	3 μM Compound: 2	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
A549	IC₅₀	7.2 μM Compound: 2	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
A549	IC₅₀	8.9 μM Compound: PL ; 1	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
ACHN	EC₅₀	3.7 μM Compound: 6	Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay	[PMID: 22313254]
ACHN	EC₅₀	7.3 μM Compound: 6	Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL	[PMID: 22313254]
B16-F10	IC₅₀	1 μM Compound: 2	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
BT-474	IC₅₀	0.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay	[PMID: 22512718]
BT-474	IC₅₀	1.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay	[PMID: 22512718]
DU-145	IC₅₀	5.23 μM Compound: Plumbagin	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HCT-116	IC₅₀	20 μM Compound: 1	Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
HCT-116	IC₅₀	20 μM Compound: 1	Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
HCT-116	IC₅₀	9.8 μM Compound: PL ; 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HEK293	EC₅₀	0.46 μM Compound: 7	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HeLa	IC₅₀	> 50 μM Compound: 18a	Inhibition of PCAF in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis Inhibition of PCAF in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis	[PMID: 31195169]
HeLa	IC₅₀	20 μM Compound: 18a	Inhibition of P300 in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis Inhibition of P300 in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis	[PMID: 31195169]
HeLa	IC₅₀	25.5 μM Compound: 1a	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24913712]
HeLa	IC₅₀	59 μM Compound: 1b	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HepG2	IC₅₀	10.66 μM Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
HepG2	IC₅₀	9.17 μM Compound: PL ; 1	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HK-2	IC₅₀	23.58 μM Compound: PL ; 1	Cytotoxicity against human HK2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HL-60	IC₅₀	1.1 μM Compound: 2	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HL-60	IC₅₀	3.67 μM Compound: Plumbagin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 30007564]
HL-60	IC₅₀	8.25 μM Compound: Plumbagin	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 30007564]
Hs 683	IC₅₀	4 μM Compound: 2	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
HT-29	IC₅₀	26.2 μM Compound: 1b	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	4.19 μM Compound: Plumbagin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
Jurkat	IC₅₀	0.95 μM Compound: 2	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
LS174T	IC₅₀	9.9 μM Compound: 2	Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	12.2 μM Compound: 1b	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	2.84 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	3 μM Compound: 2	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
MCF7	IC₅₀	3.35 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 33234343]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30810041]
MCF7	IC₅₀	4.1 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	5.1 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	5.5 μM Compound: 1	Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 22483392]
MCF7/PTX	IC₅₀	3.5 μM Compound: Plumbagin	Cytotoxicity against paclitaxel-resistant human MCF7/PTX cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human MCF7/PTX cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30810041]
MDA-MB-231	IC₅₀	14.23 μM Compound: 1; PL	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
MDA-MB-231	IC₅₀	21.24 μM Compound: Plumbagin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
MDA-MB-231	IC₅₀	3.5 μM Compound: 1	Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22483392]
MDA-MB-231	IC₅₀	4.4 μM Compound: Plumbagin	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33234343]
MDA-MB-231	IC₅₀	51.12 μM Compound: 1b	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	6.5 μM Compound: PL ; 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
MDA-MB-453	IC₅₀	34.56 μM Compound: 1b	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-468	IC₅₀	2.5 μM Compound: 1	Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 22483392]
ME-180	IC₅₀	43.4 μM Compound: 1b	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MONO-MAC-6	IC₅₀	2.6 μM Compound: 2	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PBMC	EC₅₀	0.8 μM Compound: 1	Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry	[PMID: 22019229]
PBMC	IC₅₀	2.7 μM Compound: 2	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PC-3	IC₅₀	17.19 μM Compound: 1b	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
SAS	IC₅₀	3 μM Compound: 1a	Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24913712]
Sf21	IC₅₀	2 μM Compound: 99	Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate	10.1039/C1MD00199J
Sf9	IC₅₀	> 100 μM Compound: 4, ZINC-58187	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	[PMID: 20580552]
SK-BR-3	IC₅₀	1.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay	[PMID: 22512718]
SK-BR-3	IC₅₀	3.2 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay	[PMID: 22512718]
SK-MEL-28	IC₅₀	5 μM Compound: 2	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
SMMC-7721	IC₅₀	2.43 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 24 hrs Antitumor activity against human SMMC-7721 cells measured after 24 hrs	[PMID: 34669417]
SMMC-7721	IC₅₀	36.05 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 6 hrs Antitumor activity against human SMMC-7721 cells measured after 6 hrs	[PMID: 34669417]
SMMC-7721	IC₅₀	5.41 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 12 hrs Antitumor activity against human SMMC-7721 cells measured after 12 hrs	[PMID: 34669417]
SW480	IC₅₀	12 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
SW480	IC₅₀	7.3 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24828199]
SW-620	IC₅₀	7.4 μM Compound: 1	Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24828199]
SW-620	IC₅₀	7.7 μM Compound: 1	Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
SW982	IC₅₀	3.6 μM Compound: 2	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
THP-1	IC₅₀	1.1 μM Compound: 2	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
U-373MG ATCC	IC₅₀	5 μM Compound: 2	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
U-937	IC₅₀	2.4 μM Compound: 2	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
WI-38	IC₅₀	26.71 μM Compound: Plumbagin	Cytotoxicity against human WI38 cells after 48 hrs by MTT assay Cytotoxicity against human WI38 cells after 48 hrs by MTT assay	[PMID: 30007564]
WRL68	IC₅₀	15.36 μM Compound: PL ; 1	Cytotoxicity against human WRL68 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human WRL68 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]

体外研究
(In Vitro)

Plumbagin (0、5、10 和 15 μM) 以剂量依赖的方式诱导前列腺癌细胞系的凋亡，例如 DU145、CWR22rv1 和 LNCaP^[1]。
(5，20 μM) 显著抑制 PC3、DU145、CWR22rv1 细胞的侵袭^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	DU145, CWR22rv1, LNCaP and RWPE-1 cells
Concentration:	0, 5, 10, and 15 μM
Incubation Time:	24 hours
Result:	Dose-dependently induced apoptosis of DU145, CWR22rv1 and LNCaP, but showed no effect on RWPE-1 cells at up to 20 μM.

体内研究
(In Vivo)

Plumbagin (2 mg/kg，ip，每周 5 天，持续 11 周) 抑制雄性无胸腺裸鼠肿瘤的生长^[1]。
Plumbagin (2 mg/kg，ip，每周 5 天，持续 11 周) 在小鼠中抑制 PKCε 的表达，抑制 JAK-2 和 Stat3 磷酸化，并激活 Stat3、PCNA、VEGF 和 MMP-9^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice bearing DU145 cells^[1]
Dosage:	2 mg/kg
Administration:	I.P. after 3 days post cell implantation, five days a week.
Result:	Delayed tumor growth by 3 weeks, and reduced tumor weight and volume in mice.

分子量

188.18

Formula

C₁₁H₈O₃

CAS 号

481-42-5

性状

固体

颜色

Light yellow to orange

中文名称

白花丹素；白花丹醌

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 150 mg/mL (797.11 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.3141 mL	26.5703 mL	53.1406 mL
5 mM	1.0628 mL	5.3141 mL	10.6281 mL
10 mM	0.5314 mL	2.6570 mL	5.3141 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.05 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (11.05 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.39%

选择批次：

Data Sheet (639 KB) SDS (480 KB)

COA (291 KB) LCMS (91 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Aziz MH, et al. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008 Nov 1;68(21):9024-32. [Content Brief]

Plumbagin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.3141 mL	26.5703 mL	53.1406 mL	132.8515 mL
	5 mM	1.0628 mL	5.3141 mL	10.6281 mL	26.5703 mL
	10 mM	0.5314 mL	2.6570 mL	5.3141 mL	13.2852 mL
	15 mM	0.3543 mL	1.7714 mL	3.5427 mL	8.8568 mL
	20 mM	0.2657 mL	1.3285 mL	2.6570 mL	6.6426 mL
	25 mM	0.2126 mL	1.0628 mL	2.1256 mL	5.3141 mL
	30 mM	0.1771 mL	0.8857 mL	1.7714 mL	4.4284 mL
	40 mM	0.1329 mL	0.6643 mL	1.3285 mL	3.3213 mL
	50 mM	0.1063 mL	0.5314 mL	1.0628 mL	2.6570 mL
	60 mM	0.0886 mL	0.4428 mL	0.8857 mL	2.2142 mL
	80 mM	0.0664 mL	0.3321 mL	0.6643 mL	1.6606 mL
	100 mM	0.0531 mL	0.2657 mL	0.5314 mL	1.3285 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Plumbagin481-42-52-Methyljuglone白花丹素白花丹醌OthersInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Plumbagin (Synonyms: 白花丹素; 2-Methyljuglone)

Customer Review

Other Forms of Plumbagin:

MCE 顾客使用本产品发表的 2 篇科研文献

Plumbagin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Plumbagin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Plumbagin (Synonyms: 白花丹素; 2-Methyljuglone)

Customer Review

Other Forms of Plumbagin:

Plumbagin 相关抗体

MCE 顾客使用本产品发表的 2 篇科研文献

Plumbagin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Plumbagin 相关抗体:

摩尔计算器

稀释计算器

Plumbagin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z